Cargando…

Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study

OBJECTIVES: This study evaluated the comparative effectiveness of a tumour necrosis factor inhibitor (TNFi) versus a non-TNFi (biological disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs)) as the first-line treatment following conventional synthetic DMARDs, as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pappas, Dimitrios A, St John, Gregory, Etzel, Carol J, Fiore, Stefano, Blachley, Taylor, Kimura, Toshio, Punekar, Rajeshwari, Emeanuru, Kelechi, Choi, Jeannie, Boklage, Susan, Kremer, Joel M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Recommendation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7788059/ https://www.ncbi.nlm.nih.gov/pubmed/32719038 http://dx.doi.org/10.1136/annrheumdis-2020-217209

Ejemplares similares

The effect of targeted rheumatoid arthritis therapeutics on systemic inflammation and anemia: analysis of data from the CorEvitas RA registry
por: Padula, Anthony S., et al.
Publicado: (2022)

Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis
por: Huynh, D H, et al.
Publicado: (2017)

Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2020)

Clinical Outcomes in Patients with Rheumatoid Arthritis After Switching Between Interleukin-6-Receptor Inhibitors and Janus Kinase Inhibitors: Findings from an Observational Study
por: Dua, Anisha B., et al.
Publicado: (2023)

Durability of Response to Tocilizumab Therapy in Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2021)

Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2021)

Tumour necrosis factor inhibitors in Crohn's disease and the effect on surgery rates
por: Eberhardson, Michael, et al.
Publicado: (2022)

Exploring sub-optimal response to tumour necrosis factor inhibitors in axial spondyloarthritis
por: Yahya, Fariz, et al.
Publicado: (2019)

Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far
por: Jani, Meghna, et al.
Publicado: (2018)

Early Lyme Borreliosis in Patients Treated with Tumour Necrosis Factor-Alfa Inhibitors
por: Maraspin, Vera, et al.
Publicado: (2019)

Central Nervous System Demyelination Related to Tumour Necrosis Factor Alpha Inhibitor
por: Chey, Shin Yee, et al.
Publicado: (2022)

The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor
por: Harrold, Leslie R, et al.
Publicado: (2015)

A stonemason with accelerated silicosis in the setting of tumour necrosis factor alpha inhibitor therapy
por: Baird, Timothy, et al.
Publicado: (2016)

Smoking status and cause-specific discontinuation of tumour necrosis factor inhibitors in axial spondyloarthritis
por: Zhao, Sizheng Steven, et al.
Publicado: (2019)

TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases
por: Totzke, Juliane, et al.
Publicado: (2020)

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
por: Nash, Peter, et al.
Publicado: (2021)

Carnitine and congeners as regulators of tumour necrosis factor
por: De Simone, Claudio, et al.
Publicado: (1993)

Tumour necrosis factor-α in nasal allergy
por: Hisamatsu, K., et al.
Publicado: (1995)

Tumour necrosis factor signalling in health and disease
por: Holbrook, Jonathan, et al.
Publicado: (2019)

Tumour necrosis factor production and natural killer cell activity in peripheral blood during treatment with recombinant tumour necrosis factor.
por: MÃ¤nnel, D. N., et al.
Publicado: (1989)

Portuguese recommendations for the treatment of atopic dermatitis with biologic therapy and JAK inhibitors in adult patients
por: Torres, Tiago, et al.
Publicado: (2021)

Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis
por: Massey, Jonathan, et al.
Publicado: (2018)

Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19
por: Patel, Serena, et al.
Publicado: (2021)

Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis
por: Glossop, John R, et al.
Publicado: (2005)

A Study of Single Nucleotide Polymorphisms of Tumour Necrosis Factor α-1031 And Tumour Necrosis Factor β+ 252 in Chronic Rhinosinusitis
por: Misron, Khairunnisak, et al.
Publicado: (2017)

EULAR recommendations for a core data set for pregnancy registries in rheumatology
por: Meissner, Yvette, et al.
Publicado: (2021)

Tumour necrosis factor inhibitor tapering in patients with ankylosing spondylitis at low disease activity: factors associated with flare
por: Kwon, Oh Chan, et al.
Publicado: (2021)

EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors
por: Kostine, Marie, et al.
Publicado: (2021)

Effects on tumour microcirculation in mice of misonidazole and tumour necrosis factor plus hyperthermia.
por: Fujimoto, S., et al.
Publicado: (1992)

Tumour necrosis factor in man: clinical and biological observations.
por: Selby, P., et al.
Publicado: (1987)

Tumour necrosis factor-dependent inflammatory cartilage destruction
por: Korb, A, et al.
Publicado: (2007)

Tumour necrosis factor inhibitors reduce aortic stiffness progression in patients with long-standing rheumatoid arthritis
por: Giollo, Alessandro, et al.
Publicado: (2021)

Molecular design of hybrid tumour necrosis factor-alpha. II: The molecular size of polyethylene glycol-modified tumour necrosis factor-alpha affects its anti-tumour potency.
por: Tsutsumi, Y., et al.
Publicado: (1996)

Enhanced anti-tumour activity of carmustine (BCNU) with tumour necrosis factor in vitro and in vivo.
por: Jones, A. L., et al.
Publicado: (1990)

Tumour-infiltrating lymphocytes bear the 75 kDa tumour necrosis factor receptor.
por: Trentin, L., et al.
Publicado: (1995)

Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study
por: Ochi, Sae, et al.
Publicado: (2020)

Primary Cutaneous B-cell Lymphoma Leg-type Related to a Tumour Necrosis Factor Alpha Inhibitor
por: BELKAÏD, Samy, et al.
Publicado: (2022)

Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors
por: Weitz, Jeffrey I, et al.
Publicado: (2022)

Role of prostaglandins in tumour necrosis factor induced weight loss.
por: Mahony, S. M., et al.
Publicado: (1989)

Tumour necrosis factor: a cytokine with multiple biological activities.
por: Semenzato, G.
Publicado: (1990)

Cannot write session to /tmp/vufind_sessions/sess_b5g77soogr205raafklhacnrvc